Verto Md

VERTO MD is a privately held service-providing company specializing in clinical research and development in the field of medical sciences and biotechnology, as well as the development, management, and monitoring of clinical trials. The main VERTO MD therapeutic areas include immunology and oncology, having experience in indications including but not limited to niche or orphan indications like CD37+, CD123+, CD70+, CD30+, CD33+, CD19+, CD20+, CD3+, expressing malignancies, FcRn, PD-1/PDL-1, single and multi targeting therapeutics, NOTCH signaling, TNFs, HDAC inhibition, proteasome inhibitors. VERTO MD contributes to global research activities and complex international projects in geographic areas such as the USA, European Union (EU) with strong expertise in Central and Eastern Europe (CEE); Middle East, Turkey, and Africa (META); South Asia & Australia (APAC); Russia & CIS; Latin America (LATAM); China and Hong Kong.